- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Novartis Prepares to Defend Omalizumab Market as Potential Biosimilars Advance
In October, the FDA granted approval for a pre-filled syringe formulation of the reference product. Additionally, Novartis is looking to expand omalizumab’s indications, as it recently earned FDA’s breakthrough therapy designation in August 2018 as a treatment for food allergies.
Novartis recently announced that ligelizumab, a monoclonal antibody being investigated for the treatment of chronic spontaneous urticaria (CSU), will move on to phase 3 trials after demonstrating a clear dose-response relationship and improvements over another 1 of its older products, omalizumab (Xolair), in this cohort.
“Despite existing treatment options, too many people continue to struggle with the debilitating and potentially painful symptoms of CSU. Advancing ligelizumab to phase 3 is encouraging news for physicians and patients who have difficulty in controlling symptoms,” said Marcus Maurer, MD, professor of dermatology and allergy and director of research at the Department of Dermatology and Allergy of Charite-Universitätsmedizin in Berlin, Germany.
The trials come as welcome good news to Novartis, as the company looks to protect market share after omalizumab lost patent protection in the United States in June 2017, and in Europe in August 2017. Though omalizumab biosimilars have yet to be approved in either of the regulatory territories, at least 2 biosimilars are currently in development.
In July 2018, Glenmark Pharmaceuticals announced that its phase 1 study of GBR 310, a proposed omalizumab biosimilar, revealed similar pharmacokinetic, pharmacodynamic, safety, and immunogenicity profiles between its proposed omalizumab biosimilar and the reference Xolair.
Likewise, Sorrento Therapeutics, Inc, in collaboration with Mabtech, completed a combined phase 2 and phase 3 trial of STI-004 in China in 2016. Though the developers have not yet announced a filing of a Biologics License Application with the FDA, the potential biosimilar met its primary end point in the multicenter, randomized, double-blind, placebo-controlled trial.
Novartis, for its part, is fighting back against encroaching challengers in this therapeutic space. In October, the FDA granted approval for a pre-filled syringe formulation of the reference product. Additionally, Novartis is looking to expand omalizumab’s indications, as it recently earned FDA’s breakthrough therapy designation in August 2018 as a treatment for food allergies. In 2017, omalizumab brought in $1.75 billion in the United States alone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
January 31st 2025The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.
